A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

Trial Profile

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2015

At a glance

  • Drugs Lenvatinib (Primary) ; Rifampicin
  • Indications Adenocarcinoma; Endometrial cancer; Glioma; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 01 Dec 2013 New trial record
    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top